The first stop for professional medicines advice

Medicines planning

62 results

Applied filters

Delegation of roles under a PGD

19 March 2024Delegation of any PGD function is not permitted. However there are specific tasks that individuals other than the professional working under a PGD can fulfil.

Good governance when implementing eculizumab biosimilar

6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for eculizumab biosimilars

6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.

Preparing to use eculizumab biosimilar

6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing tocilizumab biosimilar

5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for tocilizumab biosimilar

5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.

Preparing to use tocilizumab biosimilar

5 March 2024Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Good governance when implementing natalizumab biosimilar

6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.